Home > Insider Trading > Filing (0001209191-20-012484)

Filing Details

Accession Number:: 0001209191-20-012484
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2020-02-25 16:36:40
Reporting Period:: 2020-02-21

Accepted Time:: 2020-02-25 16:36:40
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1446847	Ironwood Pharmaceuticals Inc	IRWD	Pharmaceutical Preparations (2834)	043404176

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1781117	Kelly Macdonald	C/O Ironwood Pharmaceuticals, Inc. 100 Summer Street, Suite 2300 Boston MA 02110	Chief Accounting Officer	No	Yes	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Class A Common Stock	Disposition	2020-02-21	302	$11.63	86,725	No	4	S	Direct
Class A Common Stock	Disposition	2020-02-21	504	$11.63	86,221	No	4	S	Direct
Class A Common Stock	Disposition	2020-02-21	303	$11.63	85,918	No	4	S	Direct
Class A Common Stock	Disposition	2020-02-21	793	$11.63	85,125	No	4	S	Direct
Class A Common Stock	Disposition	2020-02-21	303	$11.63	84,822	No	4	S	Direct
Class A Common Stock	Disposition	2020-02-21	1,695	$11.63	83,127	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct

Footnotes

This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. This sale was made to cover tax withholding obligations in connection with vesting and settlement of approximately 25% of the reporting person's restricted stock units granted on March 1, 2016.
The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $11.58 to $11.64, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
The reporting person acquired 460 shares of Class A common stock under the issuer's employee stock purchase plan on December 31, 2019.
This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. This sale was made to cover tax withholding obligations in connection with vesting and settlement of approximately 25% of the reporting person's restricted stock units granted on February 27, 2017.
This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. This sale was made to cover tax withholding obligations in connection with vesting and settlement of approximately 25% of the reporting person's restricted stock units granted on May 1, 2017.
This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. This sale was made to cover tax withholding obligations in connection with vesting and settlement of approximately 25% of the reporting person's restricted stock units granted on February 21, 2018.
This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. This sale was made to cover tax withholding obligations in connection with vesting and settlement of approximately 25% of the reporting person's restricted stock units granted on May 1, 2018.
This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. This sale was made to cover tax withholding obligations in connection with vesting and settlement of approximately 25% of the reporting person's restricted stock units granted on January 29, 2019.